EGFR-targeted agents include small molecule receptor tyrosine kinase inhibitors (RTKIs) and monoclonal antibodies licenced for treatment of NSCLC, breast cancer and colorectal cancer [33,34]. Here, NTRK1 is linked to breast carcinoma.